The changing landscape of phase I trials in oncology, Nature Reviews Clinical Oncology, vol.20, issue.2, pp.106-123, 2016. ,
DOI : 10.1358/dot.2015.51.3.2294597
What makes Clinical Research Ethical? JAMA May 24/31, 2000. ,
DOI : 10.1001/jama.283.20.2701
Semi-parametric dose finding methods, Journal of the Royal Statistical Society, Series B (Statistical Methodology), 2017. ,
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer, Biometrics, vol.46, issue.1, pp.33-48, 1990. ,
DOI : 10.2307/2531628
Design efficiency in dose finding studies, Computational Statistics & Data Analysis, vol.45, issue.2, pp.197-214, 2004. ,
DOI : 10.1016/S0167-9473(02)00323-7
Design Considerations for Dose-Expansion Cohorts in Phase I Trials, Journal of Clinical Oncology, vol.31, issue.31, pp.4014-4035, 2013. ,
DOI : 10.1200/JCO.2012.47.9949
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979131
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents ? Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study, European Journal of Cancer, vol.50, issue.12, pp.2040-2049, 2014. ,
DOI : 10.1016/j.ejca.2014.04.031
A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults? trials, European Journal of Cancer, vol.49, issue.10, pp.2392-402, 2013. ,
DOI : 10.1016/j.ejca.2013.02.028
Phase I trials in oncology: a new era has started, Annals of Oncology, vol.26, issue.1, pp.7-9, 2015. ,
DOI : 10.1093/annonc/mdu513